Fiona MacLaughlin

Fiona MacLaughlin is the founder of Arrakis Therapeutics, Inc., founded in 2015.
Current jobs include Non-Executive Director at Pulmocide Ltd. since 2020, Non-Executive Director at Syndesi Therapeutics SA since 2020, Non-Executive Director at Calypso Biotech BV since 2020, Non-Executive Director at Mestag Therapeutics Ltd. since 2020, Principal at Johnson & Johnson Innovation - JJDC, Inc. since 2020, and Associate at Advent Life Sciences LLP since 2012.
Former jobs include Director at INKEF Capital BV from 2017 to 2020, Director at ONWARD Medical SA, Non-Executive Director at GTX medical BV from 2018 to 2020, Non-Executive Director at NMD Pharma A from 2019 to 2020, Non-Executive Director at iOnctura SA from 2019 to 2020, Associate at Advent Venture Partners LLP from 2012 to 2017, Senior Business Analyst at Wellcome Trust Technology Transfer, Head-Research and Development at Gendel Ltd. from 1997 to 2002, Principal at Odontis Ltd., Head-Strategic Business & Product Development at RepRegen Ltd., Head of Strategic Business Development at RepRegen Ltd. from 2010 to 2012, Strategic Adviser at Tiber Creek Partners LLC from 2010 to 2012, Business Development Manager at The Wellcome Trust Ltd. (Investment Management) from 2005 to 2010, and Advisory Board Member at Apollo Therapeutics No.
2 LLP from 2020 to 2021.
Education includes a doctorate conferred in 1996 and an undergraduate degree conferred in 1992, both from The University of Nottingham.